Eisler Capital (Us) LLC Abb Vie Inc. Call Options Transaction History

Eisler Capital (Us) LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $12.6 Million - $15.3 Million	-76,900 Reduced 48.73%	80,900 $16 Billion
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $16.3 Million - $19 Million	105,200 Added 200.0%	157,800 $27.1 Billion
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $2.13 Million - $2.42 Million	-13,300 Reduced 20.18%	52,600 $9.58 Billion
Q4 2023 Feb 13, 2024	SELL	$137.6 - $154.97 $8.13 Million - $9.16 Million	-59,100 Reduced 47.28%	65,900 $10.2 Billion
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $13.4 Million - $15.5 Million	100,300 Added 406.07%	125,000 $18.6 Billion
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $2.12 Million - $2.64 Million	16,000 Added 183.91%	24,700 $3.33 Billion
Q1 2023 May 12, 2023	BUY	$144.61 - $166.54 $1.26 Million - $1.45 Million	8,700 New	8,700 $1.39 Billion

3,848

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Eisler Capital (Us) LLC, based on Form 13F filings with the SEC.

Stay updated on Eisler Capital (Us) LLC with notifications on news.